Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Tom Frohlich

Tom Frohlich

Chief Executive Officer, Jade Biosciences

Appears in 1 story

Notable Quotes

Frohlich said the Phase 1 readout supports a once-quarterly dosing schedule, which he called a meaningful step beyond the monthly injections available today.

Stories

IgA nephropathy gains five approved drugs in four years

New Capabilities

Leading JADE101 through Phase 2 with Phase 3 planned for 1H 2027

For decades, doctors had no drugs specifically approved for IgA nephropathy, a kidney disease that pushes up to half of patients toward kidney failure within ten years of diagnosis. Since December 2021, the FDA has approved five.

Updated Yesterday